Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | DRD4 | P21917 | 2/20 | 0.30 |
| ▸ | DRD3 | P35462 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165132 | 0.89 | PTGDR2 (0.37) | PTGDR2 | |
| SCHEMBL4419771 | 0.86 | PTGDR2 (0.36) | PTGDR2DRD2DRD4DRD3 | |
| SCHEMBL12678732 | 0.84 | POLB (0.37) | PTGDR2 | |
| SCHEMBL3159313 | 0.80 | PTGDR2 (0.34) | PTGDR2DRD2DRD4DRD3 | |
| SCHEMBL3169747 | 0.79 | PTGDR2 (0.43) | PTGDR2 | |
| SCHEMBL27771716 | 0.76 | PTGDR2 (0.34) | PTGDR2DRD2DRD4DRD3 | |
| SCHEMBL3165002 | 0.75 | PDCD1 (0.37) | DRD2DRD4DRD3 | |
| SCHEMBL3176967 | 0.72 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL3173411 | 0.71 | ALDH1A1 (0.37) | PTGDR2 | |
| SCHEMBL3166129 | 0.66 | PTGDR2 (0.44) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| CN-102442941-A | Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents | ASTELLAS PHARMA INC | 2012-05-09 | — | — | CN | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| CN-101636386-A | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC | 2010-01-27 | — | — | CN | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | PTGDR2 116/4885DRD2 621/4885DRD4 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.